Who was studied?
9 patients with MSS/pMMR metastatic colorectal cancer from the original and cytokine-extended trials.
What does the publication report?
ORR was 22.2%, DCR 66.7% and median PFS 5.6 months.
Safety findings
7 patients (77.8%) had treatment-related events; 1 (11.1%) had grade 3 renal insufficiency.
How should we interpret it?
Small, pooled subgroup reported as a conference abstract. These patients overlap with the parent trials and do not form a new independent trial.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
The response of PD-1 inhibitor combined with Radiotherapy and GM-CSF(PRaG) with or without IL-2 in microsatellite stable metastatic colorectal cancer: Analysis of pooled data from two phase II trials. · DOI: 10.1200/JCO.2022.40.16_suppl.e15561
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.